Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065447 | 0.70 | ALDH1A1 (0.50) | ALDH1A1LMNANOTUMMAPT | |
| SCHEMBL5065400 | 0.69 | IKBKB (0.44) | ALDH1A1LMNAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1693615 | 0.69 | PIK3CD (0.43) | ALDH1A1LMNAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL5067504 | 0.66 | ALDH1A1 (0.40) | ALDH1A1LMNANOTUM | |
| SCHEMBL5064776 | 0.66 | ADORA3 (0.50) | — | |
| SCHEMBL5064152 | 0.66 | PIK3CD (0.40) | ALDH1A1LMNAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL5064749 | 0.65 | MAPT (0.49) | ALDH1A1LMNAMAPT | |
| SCHEMBL4800416 | 0.65 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL4796320 | 0.64 | TEK (0.72) | LMNA | |
| SCHEMBL5064157 | 0.64 | ALDH1A1 (0.41) | ALDH1A1LMNANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | ALDH1A1 1911/4885LMNA 4401/4885PIK3CD 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.